<p>波士顿，2025 年 6 月 20 日（环球新闻通讯社）——Inozyme Pharma, Inc.（纳斯达克：INZY）今天宣布，鉴于 BioMarin Pharmaceutical Inc.（“BioMarin”）之前宣布的收购（“收购”），已推迟原定于 2025 年 6 月 25 日举行的 2025 年股东年会（“年会”）。</p>
<p>如果收购完成，将不会举行涉及公众股东的年会。如果收购未完成，董事会将采取其认为适当的进一步行动，以在稍后日期召集和召开年会，包括设定新的记录日期以确定有权在年会上投票的股东。</p>
<p><strong>关于 Inozyme</strong></p>
<p>Inozyme Pharma 是一家临床阶段的生物制药公司，约有 50 名员工，位于波士顿。该公司致力于开发针对 PPi-腺苷通路的创新疗法，这是一种骨骼健康和血管功能的关键调节因子。该通路的中断是多种严重疾病的根源，包括 ENPP1 缺乏症。我们的主要研究治疗药物 INZ-701 是一种 ENPP1 Fc 融合蛋白酶替代疗法，旨在恢复焦磷酸盐和腺苷水平。INZ-701 目前正在 ENPP1 缺乏症的后期临床开发中，并有潜力扩展到其他因焦磷酸盐 - 腺苷通路缺乏而导致疾病病理的适应症，包括 ABCC6 缺乏症和钙化性坏死。通过我们的开创性工作，我们旨在改变受这些严重疾病影响患者的治疗选择。</p>
<p>欲了解更多信息，请访问 www.inozyme.com。</p>
<p><strong>关于收购的更多信息及获取途径</strong></p>
<p>本通讯仅供信息参考，并不构成购买要约或出售任何证券的邀请，也不是 Inozyme、BioMarin 或其收购子公司向 SEC 提交的要约收购材料的替代品。对 Inozyme 的股份进行要约收购和购买的邀请将仅根据在 TO 表格上的要约收购声明进行，包括 BioMarin 及其收购子公司 Incline Merger Sub, Inc.向 SEC 提交的购买要约及相关要约收购材料。在要约收购开始时，BioMarin 及其收购子公司提交了 TO 表格的要约收购声明，Inozyme 则向 SEC 提交了关于要约收购的征求/推荐声明（Schedule 14D-9）。要约收购材料（包括购买要约、相关的转让信及其他某些要约收购文件），以及征求/推荐声明包含有关拟议收购及相关方的重要信息。Inozyme 的投资者和股东被敦促仔细阅读这些文件（及其可能不时修订或补充的版本），因为它们包含投资者和股东在做出任何与要约收购相关的决定之前应考虑的重要信息。要约收购材料（包括购买要约、相关的转让信及其他某些要约收购文件）以及征求/推荐声明，所有 Inozyme 的投资者和股东均可在 SEC 网站 www.sec.gov 上免费获取。BioMarin 向 SEC 提交的文件副本将在 BioMarin 的网站 www.biomarin.com 上免费提供。Inozyme 向 SEC 提交的文件副本将在 Inozyme 的网站 www.inozyme.com 上免费提供，或通过联系 Inozyme 的投资者关系部门（investorrelations@inozyme.com）获取。通过 BioMarin 和 Inozyme 的网站获取的信息不构成本声明的一部分或引用。此外，除了购买要约、相关的转让信及其他某些要约收购文件和征求/推荐声明外，BioMarin 和 Inozyme 还向 SEC 提交年度、季度和当前报告、代理声明及其他信息。您可以在 SEC 网站 www.sec.gov 上免费阅读 BioMarin 和 Inozyme 向 SEC 提交的任何报告、声明或其他信息。</p>
<p><strong>投资者关系联系方式：</strong></p>
<p>Inozyme Pharma</p>
<p>Stefan Riley，投资者关系及企业传播高级总监</p>
<p>(617) 461-2442</p>
<p>Stefan.riley@inozyme.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRM01qRTFNU00zTURBeE5URXlJekl5TURBM09EYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRM01qRTFNU00zTURBeE5URXlJekl5TURBM09EYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Y2I0YWNlNTktYjQ3NS00OWYxLWJjODEtYzQ2ZmYxMDBhMDFkLTEyMTIzNDAtMjAyNS0wNi0yMC1lbg==/tiny/Inozyme-Pharma-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Y2I0YWNlNTktYjQ3NS00OWYxLWJjODEtYzQ2ZmYxMDBhMDFkLTEyMTIzNDAtMjAyNS0wNi0yMC1lbg==/tiny/Inozyme-Pharma-Inc-.png"/></p>

INZY

<p>Inozyme Pharma, Inc. 已经推迟了原定于 2025 年 6 月 25 日举行的 2025 年股东年会，原因是其被 BioMarin Pharmaceutical Inc.收购。如果收购完成，将不会为公众股东召开会议。如果未完成，董事会将于稍后重新召开会议。Inozyme 专注于开发针对 PPi-腺苷通路的疗法，其主要疗法 INZ-701 正在针对 ENPP1 缺乏症的晚期临床开发中</p>

<p>BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”).</p>
<div class="lb-trans"><p>波士顿，2025 年 6 月 20 日（环球新闻通讯社）——Inozyme Pharma, Inc.（纳斯达克：INZY）今天宣布，鉴于 BioMarin Pharmaceutical Inc.（“BioMarin”）之前宣布的收购（“收购”），已推迟原定于 2025 年 6 月 25 日举行的 2025 年股东年会（“年会”）。</p>
</div><p>If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take such further action as it deems appropriate to call and convene the Annual Meeting at a later date, including the establishment of a new record date for determining the stockholders entitled to vote at the Annual Meeting.</p>
<div class="lb-trans"><p>如果收购完成，将不会举行涉及公众股东的年会。如果收购未完成，董事会将采取其认为适当的进一步行动，以在稍后日期召集和召开年会，包括设定新的记录日期以确定有权在年会上投票的股东。</p>
</div><p><strong>About Inozyme</strong></p>
<div class="lb-trans"><p><strong>关于 Inozyme</strong></p>
</div><p>Inozyme Pharma is a clinical-stage biopharmaceutical company, with approximately 50 employees based in Boston. The company is dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions.</p>
<div class="lb-trans"><p>Inozyme Pharma 是一家临床阶段的生物制药公司，约有 50 名员工，位于波士顿。该公司致力于开发针对 PPi-腺苷通路的创新疗法，这是一种骨骼健康和血管功能的关键调节因子。该通路的中断是多种严重疾病的根源，包括 ENPP1 缺乏症。我们的主要研究治疗药物 INZ-701 是一种 ENPP1 Fc 融合蛋白酶替代疗法，旨在恢复焦磷酸盐和腺苷水平。INZ-701 目前正在 ENPP1 缺乏症的后期临床开发中，并有潜力扩展到其他因焦磷酸盐 - 腺苷通路缺乏而导致疾病病理的适应症，包括 ABCC6 缺乏症和钙化性坏死。通过我们的开创性工作，我们旨在改变受这些严重疾病影响患者的治疗选择。</p>
</div><p>To learn more, please visit www.inozyme.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.inozyme.com。</p>
</div><p><strong>Additional Information About the Acquisition and Where to Find It</strong></p>
<div class="lb-trans"><p><strong>关于收购的更多信息及获取途径</strong></p>
</div><p>This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Inozyme, BioMarin or its acquisition subsidiary has filed with the SEC. The solicitation and offer to tender and the offer to buy outstanding shares of Inozyme will only be made pursuant to a tender offer statement on Schedule TO, including an Offer to Purchase and related tender offer materials that BioMarin and its acquisition subsidiary, Incline Merger Sub, Inc., has filed with the SEC. At the time the tender offer commenced, BioMarin and its acquisition subsidiary filed a Tender Offer Statement on Schedule TO, and Inozyme filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), AS WELL AS THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF INOZYME ARE URGED TO READ THESE DOCUMENTS CAREFULLY (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF INOZYME SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER. The tender offer materials (including the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents), as well as the Solicitation/Recommendation Statement, are available to all investors and stockholders of Inozyme at no expense to them at SEC's website at www.sec.gov. Copies of the documents filed with the SEC by BioMarin will be available free of charge on BioMarin's website at www.biomarin.com. Copies of the documents filed with the SEC by Inozyme will be available free of charge on Inozyme's website, www.inozyme.com, or by contacting Inozyme's investor relations department at investorrelations@inozyme.com. The information contained in, or that can be accessed through, BioMarin's and Inozyme's websites is not a part of, or incorporated by reference herein. In addition to the Offer to Purchase, related Letter of Transmittal and certain other tender offer documents, and Solicitation/Recommendation Statement, BioMarin and Inozyme file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by BioMarin and Inozyme with the SEC for free on the SEC's website at www.sec.gov.</p>
<div class="lb-trans"><p>本通讯仅供信息参考，并不构成购买要约或出售任何证券的邀请，也不是 Inozyme、BioMarin 或其收购子公司向 SEC 提交的要约收购材料的替代品。对 Inozyme 的股份进行要约收购和购买的邀请将仅根据在 TO 表格上的要约收购声明进行，包括 BioMarin 及其收购子公司 Incline Merger Sub, Inc.向 SEC 提交的购买要约及相关要约收购材料。在要约收购开始时，BioMarin 及其收购子公司提交了 TO 表格的要约收购声明，Inozyme 则向 SEC 提交了关于要约收购的征求/推荐声明（Schedule 14D-9）。要约收购材料（包括购买要约、相关的转让信及其他某些要约收购文件），以及征求/推荐声明包含有关拟议收购及相关方的重要信息。Inozyme 的投资者和股东被敦促仔细阅读这些文件（及其可能不时修订或补充的版本），因为它们包含投资者和股东在做出任何与要约收购相关的决定之前应考虑的重要信息。要约收购材料（包括购买要约、相关的转让信及其他某些要约收购文件）以及征求/推荐声明，所有 Inozyme 的投资者和股东均可在 SEC 网站 www.sec.gov 上免费获取。BioMarin 向 SEC 提交的文件副本将在 BioMarin 的网站 www.biomarin.com 上免费提供。Inozyme 向 SEC 提交的文件副本将在 Inozyme 的网站 www.inozyme.com 上免费提供，或通过联系 Inozyme 的投资者关系部门（investorrelations@inozyme.com）获取。通过 BioMarin 和 Inozyme 的网站获取的信息不构成本声明的一部分或引用。此外，除了购买要约、相关的转让信及其他某些要约收购文件和征求/推荐声明外，BioMarin 和 Inozyme 还向 SEC 提交年度、季度和当前报告、代理声明及其他信息。您可以在 SEC 网站 www.sec.gov 上免费阅读 BioMarin 和 Inozyme 向 SEC 提交的任何报告、声明或其他信息。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系方式：</strong></p>
</div><p>Inozyme Pharma</p>
<div class="lb-trans"><p>Inozyme Pharma</p>
</div><p>Stefan Riley, Senior Director of IR and Corporate Communications</p>
<div class="lb-trans"><p>Stefan Riley，投资者关系及企业传播高级总监</p>
</div><p>(617) 461-2442</p>
<div class="lb-trans"><p>(617) 461-2442</p>
</div><p>Stefan.riley@inozyme.com</p>
<div class="lb-trans"><p>Stefan.riley@inozyme.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRM01qRTFNU00zTURBeE5URXlJekl5TURBM09EYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTQ3MjE1MSM3MDAxNTEyIzIyMDA3ODc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Y2I0YWNlNTktYjQ3NS00OWYxLWJjODEtYzQ2ZmYxMDBhMDFkLTEyMTIzNDAtMjAyNS0wNi0yMC1lbg==/tiny/Inozyme-Pharma-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/Y2I0YWNlNTktYjQ3NS00OWYxLWJjODEtYzQ2ZmYxMDBhMDFkLTEyMTIzNDAtMjAyNS0wNi0yMC1lbg==/tiny/Inozyme-Pharma-Inc-.png"/></p>

Inozyme Pharma, Inc. 宣布推迟 2025 年股东年度大会 | INZY 股票新闻